Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.72 USD | +1.63% | -15.03% | +62.25% |
05-10 | Wedbush Raises Edgewise Therapeutics' PT to $31 From $26, Keeps Outperform Rating | MT |
05-09 | Edgewise Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+62.25% | 1.63B | |
+29.41% | 49.18B | |
+0.63% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.68% | 26.09B | |
-22.78% | 18.71B | |
+8.19% | 13.26B | |
+32.95% | 12.32B | |
-1.37% | 11.99B |
- Stock Market
- Equities
- EWTX Stock
- News Edgewise Therapeutics, Inc.
- Goldman Sachs Adjusts Price Target for Edgewise Therapeutics to $8 From $11, Maintains Neutral Rating